Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Introduce “Yellow Letter”for Patients
April 18, 2011
- Relaxation of Restrictions on Online Sale of OTC Drugs May Enter Agenda in May: President Kodama of JPA
April 18, 2011
- Gov't to Enforce 25% Power Cuts This Summer for Major Users Including Drug Makers
April 18, 2011
- Gov't Appeals to High Court in Iressa Case
April 18, 2011
- Taisho Acquires Hoepharma of Malaysia
April 18, 2011
- Korosho Calls on Industry to Come Up with Energy Conservation Plans
April 18, 2011
- FDA Approves 1st New Treatment for Late-stage Melanoma in Over a Decade: BMS
April 18, 2011
- Eiken Licenses LAMP Technology to OptiGene
April 18, 2011
- ASKA Begins Shipments of Thyradin Substitute
April 18, 2011
- Review Period for QAB149 for COPD Extended 3 Months by FDA
April 18, 2011
- MCM Negotiates Partnership with Clearstone of Canada in CLS Services
April 18, 2011
- Ajinomoto Obtains Domestic Rights to IBD Treatment from Dr Falk
April 18, 2011
- NEW PRODUCTS
April 18, 2011
- FDA Approves HCC Test System μTASWako i30: Wako Pure Chemical
April 18, 2011
- Production, Shipment of Sublood to Resume in Mid-April: Fuso
April 11, 2011
- RAD-AR Completes Patient Database on Antihyperlipidemics
April 11, 2011
- Gov't-Private Sector Dialogue Postponed due to Earthquake
April 11, 2011
- MTPC Aims to Resume Operations at 2 Plants in Mid-April
April 11, 2011
- ProStrakan Shareholders Accept Acquisition by Kyowa Kirin
April 11, 2011
- Shionogi Signs Agreement with Denmark on Industry-Academic Collaboration
April 11, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…